## **Erratum**

In the paper by Oh *et al.*,<sup>1</sup> the authors noticed an error in Table 2, entry for 'EF change' under column 'Later use (n = 48)'. The correct data is 13.4 ± 12.5 instead of 413.4 ± 12.5.

The publisher apologizes for this error.

## Reference

 Oh J-H, Lee J-M, Lee H-J, Hwang J, Lee CH, Cho Y-K, Park H-S, Yoon H-J, Chung J-W, Kim H, Nam C-W, Han S, Hur S-H, Youn J-C, Kim I-C. The benefits of the earlier use of sacubitril/valsartan in de novo heart failure with reduced ejection fraction patients. ESC Heart Fail. 2022; 9: 2435–2444.

© 2022 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.